Learn More
Subluxation of the second carpal bone (C2) in two racing greyhounds, and luxation associated with other carpal injuries in a Staffordshire bull terrier, were diagnosed as causes of thoracic limb lameness. The clinical signs of subluxation were subtle, with local soft tissue swelling and a pain reaction on digital pressure over the dorsal aspect of C2. In(More)
Tears of the palmar superficial fascia over the palmar extremity of the accessory carpal bone were identified as the cause of lameness in five racing greyhounds and as a coincidental finding in a Labrador retriever with an avulsion of the insertion of the flexor carpi ulnaris tendon. The lameness in the greyhounds was mild and transient, although racing(More)
Sixty-four transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) received carfilzomib (days 1, 2, 8, 9, 15, 16), 300 mg/m(2) cyclophosphamide (days 1, 8, 15), 100 mg thalidomide (days 1-28) and 40 mg dexamethasone (days 1, 8, 15, 22) in 28-day cycles (CYKLONE regimen). Carfilzomib was dose-escalated to 15/20, 20/27, 20/36 and 20/45(More)
Measurements of the electric and magnetic field strengths surrounding six laser systems and one intense pulsed light system were carried out. The results were compared to exposure limits published by cardiac device manufacturers to assess the risk of electromagnetic interference to implantable cardiac devices such as pacemakers or implantable cardioverter(More)
Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), creatinine, troponin, NT-proBNP and pre- and post-treatment(More)
Contemporary treatments have greatly extended survival in multiple myeloma (MM), and when relapse occurs, clinicians have numerous effective options at their disposal. Genetic profiling of the tumor allows for risk stratification that guides treatment selection. “Survival is improving, thanks to new treatments,” according to Angela Mayo, MS, PA-C. The(More)
  • 1